U.S. Diversified Financial Stock News

In January 2026, Delek US Holdings released a new investor presentation outlining its Enterprise Optimization Plan, expected cash flow enhancements, and capital allocation priorities, alongside benefits from recent EPA small refinery exemption relief that is projected to unlock US$400 million in cash and add US$200 million in annual cash flow. The company is also planning a major turnaround at its Big Spring refinery in early 2026 to improve reliability, optimize its crude slate, and enhance...

If you are wondering whether Organon’s current share price reflects its underlying worth, you are not alone. This article focuses on how its market price compares with its estimated value. Organon’s stock last closed at US$8.76, with recent returns of 8.8% over 7 days, 28.3% over 30 days and 21.0% year to date, while the 1 year and 3 year returns stand at 42.9% and 67.6% declines. These moves come against a backdrop of ongoing attention on Organon’s role in the pharmaceuticals and biotech...

PNC Financial Services Group (PNC) closed out FY 2025 with fourth quarter revenue of US$5.9 billion and basic EPS of US$4.88. This set the tone for a year where trailing twelve month revenue reached US$22.3 billion and EPS came in at US$16.71. Over the past year, net profit margin moved to 29.7% from 26.5%, alongside trailing earnings growth of 20.4%. This frames a results season where higher profitability and a 3.05% dividend yield sit at the center of the story for investors watching how...

Marqeta, Inc. has appointed Patti Kangwankij as Chief Financial Officer, effective February 9, 2026, and its board has authorized a US$100 million share repurchase program, while recent filings also show stock sales by a director and the Chief Administrative Officer. The combination of a seasoned CFO with deep payments experience and a sizeable buyback authorization points to a sharpened focus on capital allocation and financial discipline. We’ll now examine how the new CFO appointment,...

Gorilla Technology Group recently announced three project wins in Taiwan across public safety, port operations, and environmental protection, alongside a multi-year, approximately US$1.40 billion AI-ready data center partnership in Southeast Asia and an investment in Astrikos.ai to strengthen its AI infrastructure offerings. Together with record Q3 2025 results, 2026 revenue guidance of US$137–$200 million, and a growing project pipeline, these developments highlight Gorilla’s push to scale...

If you are wondering whether iRhythm Holdings at around US$167 a share still offers value, the key question is how its current price lines up with what the business may reasonably be worth. The stock has had a mixed run, with a 6.8% decline over the last week and a 4.0% decline over the last month, but a 54.3% return over the past year and a 67.3% return over three years add important context to that picture. Recent coverage has focused on iRhythm Holdings as a listed medical device company...

If you are wondering whether MDU Resources Group is fairly priced or not at around US$20.66, you are in the right place to size up what the market might be baking into this stock. The share price has returned 2.0% over the last week, 7.8% over the last month, 4.0% year to date, 15.8% over the last year, 97.0% over 3 years and 126.3% over 5 years, which gives plenty of context for anyone thinking about the balance of risk and reward today. Recent moves in the stock come against a backdrop of...

Compañía de Minas BuenaventuraA (BVN) has drawn fresh attention after a strong past 3 months, with the share price showing a 35.20% total return and a 22.33% move over the past month. See our latest analysis for Compañía de Minas BuenaventuraA. That recent momentum sits on top of a much longer run, with a 1 year total shareholder return of 175.85% and a 3 year total shareholder return above 3x, while the current share price is US$34.68 after a small 1 day pullback. If this kind of move has...

Viridian Therapeutics recently announced that the FDA has accepted its Biologics License Application for thyroid eye disease drug veligrotug, granting Priority Review with a target decision date of June 30, 2026, while the company also progresses a European filing and pivotal phase 3 trials for elegrobart (VRDN-003). This cluster of regulatory milestones meaningfully advances Viridian’s thyroid eye disease franchise, concentrating attention on how its pipeline could reshape treatment options...

Disc Medicine (IRON) is back in focus after the FDA extended its review of the company’s experimental therapy bitopertin, citing questions around trial data integrity and potential abuse risk. See our latest analysis for Disc Medicine. Those FDA questions and the recent executive hire have played out against a softer tape, with the 7 day share price return of 9.23% and 90 day share price return of 18.63% contrasting with a 1 year total shareholder return of 21.78% and a very large 3 year...

VisionWave Holdings (VWAV) has drawn fresh attention after Solar Drone Ltd, its wholly owned subsidiary, secured a follow-on hardware order and a new distribution agreement covering Italy and Spain for drone-enabled infrastructure services. See our latest analysis for VisionWave Holdings. The recent news pipeline, from the Solar Drone expansion across Italy and Spain to the RF technology LOI with SaverOne and the new JV platform, has come alongside a sharp pullback, with a 1 day share price...

Banco Latinoamericano de Comercio Exterior (Bladex) recently announced it had hosted a virtual investor day on March 24, 2026, where leadership reviewed progress on its 2022–2026 plan and outlined its roadmap through 2030. A key theme from the event was Bladex’s push to evolve from a specialized trade lender into a broader transactional trade banking platform for Latin America, emphasizing scalable, technology-enabled, fee-based services. We’ll now examine how Bladex’s shift toward a...

BOK Financial (BOKF) just closed out FY 2025 with fourth quarter revenue of US$589.6 million and basic EPS of US$2.91, backed by net income of US$177.3 million. Over the past year, revenue has moved from US$523.1 million in Q4 2024 to US$589.6 million in Q4 2025, while trailing twelve month EPS sits at US$9.23. With a net interest margin of 2.98% and a cost to income ratio of 64.89% in the latest quarter, the focus this season is on how efficiently the bank is turning that top line into...

How Hingham Institution for Savings' FY 2025 Numbers Set Up the Earnings Story Hingham Institution for Savings (HIFS) closed FY 2025 with fourth quarter total revenue of US$34.5 million and basic EPS of US$9.49, while trailing twelve month revenue reached US$102.8 million and EPS came in at US$25.01, setting a clear earnings marker for investors to work from. Over the past year, revenue has moved from US$65.5 million and EPS of US$12.95 on a trailing basis in Q4 2024 to US$102.8 million and...

If you are wondering whether Equinix at around US$801.78 is priced high, low, or somewhere in between, you are not alone. That is exactly what this article will unpack. The stock has seen a 0.2% move over the last 7 days, a 7.8% return over the last 30 days, a 4.9% return year to date, but a 10.4% decline over the last year. Taken together, this gives a mixed picture of recent sentiment. These shifts sit against a backdrop of ongoing interest in data centers and digital infrastructure, where...

Navient (NAVI) is back in focus after a leadership shake up that puts long time executive Steve Hauber in the Chief Financial Officer seat, consolidating oversight of finance, legal, risk and compliance. See our latest analysis for Navient. That reshuffle comes as Navient’s share price sits at US$12.51, with a 30 day share price return of 5.23% decline and a 1 year total shareholder return of 5.70% decline. This suggests recent momentum has softened even as investors weigh the upcoming 2025...

If you are wondering whether Hawkins at around US$152 is still attractively priced after a strong multi year run, this breakdown is designed to help you size up the current valuation with clear, practical checks. The share price has seen a 6.6% gain over the last 30 days, a 4.6% return year to date, and a 33.7% return over the past year, while the 3 year return is very large at close to 3x. These moves have drawn more attention to how the market is treating specialty chemical suppliers like...

On December 31, 2025, Range Resources Corporation announced it would fully redeem its US$600,000,000 8.25% senior notes due 2029 on January 15, 2026, at 101.375% of par plus accrued interest, funded via its existing revolving credit facility. This move retires high-coupon debt while shifting funding to shorter-term bank borrowing, putting the company’s balance sheet choices under closer investor and analyst scrutiny. Next, we’ll examine how funding this bond redemption through the revolving...

Earlier this week, Edgewise Therapeutics used its presentation at the 44th J.P. Morgan Healthcare Conference to outline 2026 milestones, including pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy, Phase 2 readouts for EDG-7500 in hypertrophic cardiomyopathy, and continued development of its early-stage heart failure candidate EDG-15400. A distinctive aspect of the update is Edgewise’s attempt to build an integrated neuromuscular and cardiovascular franchise, with...

Recent analyst reports on Marex Group (MRX) highlight increased optimism around the company’s earnings outlook. Several firms have revised their forecasts higher and reiterated positive ratings, drawing fresh attention to the stock. See our latest analysis for Marex Group. The recent earnings optimism has coincided with a 32.28% 90 day share price return and a 21.80% total shareholder return over the past year, suggesting momentum has been building around Marex Group, which had a last close...

Dyne Therapeutics (DYN) is back in focus after its appearance at the 44th Annual J.P. Morgan Healthcare Conference, where CEO John G. Cox outlined progress in programs targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy. See our latest analysis for Dyne Therapeutics. Despite recent enthusiasm around Dyne’s neuromuscular programs and conference visibility, the 30 day share price return of 11.61% and year to date share price return of 9.70% contrast with a 1 year total...

Why STAAR Surgical Is Back in Focus After the Failed Alcon Deal STAAR Surgical (STAA) is back on investors’ radar after shareholders rejected its cash sale to Alcon and the company confirmed it will continue as an independent, publicly traded business. That decision has quickly been followed by a broad refresh of the boardroom, new committee structures and an active search for a new chief executive, all with heavy involvement from STAAR’s largest shareholders. See our latest analysis for...

Why Worthington Enterprises is on investors’ radar today Worthington Enterprises (WOR) has been drawing attention after a mixed stretch in recent trading, with the share price drifting lower over the past month and past 3 months while longer term returns remain positive. See our latest analysis for Worthington Enterprises. At around US$53.43, the share price has eased in the short term, with a 1 day share price return of a 2.0% decline and a 90 day share price return of a 5.5% decline, while...

Event context and why it matters for PureCycle PureCycle Technologies (PCT) is in focus after partnering with Churchill Container and 4ocean to supply reusable Run It Back souvenir cups made with its recycled resin at the College Football Playoff National Championship. The program ties every 20 cups sold to the removal of one pound of ocean trash, giving PureCycle a high profile platform for its recycling technology and putting a clear environmental metric in front of fans and investors. See...